01

Estee Lauder released the latest research findings at CDA.

Recently, the globally renowned skincare brand Estee Lauder participated in the 19th Annual Meeting of the Dermatology Physicians of the Chinese Medical Association and the National Conference on Beauty and Skin Science (CDA), where it presented the latest research results. At this CDA conference, Estee Lauder primarily published and communicated the brand's latest research成果 and breakthrough skincare technology through academic posters, focusing on themes of nighttime skincare technology (Night), skin reverse aging (Longevity), and collagen research (Collagen), submitting a total of 11 posters that showcased Estee Lauder's outstanding achievements in skincare scientific research and technological innovation.

At the CDA conference, two Nobel Prize-derived technology posters from the Estee Lauder Little Brown Bottle family, namely 'Key Targets Related to Multiple Biological Pathways in Skin Aging—Epigenetic Signaling Molecule miR-146a' and 'The Importance of Synchronization of Cellular Circadian Rhythm for Skin Health and Integrity,' became a major highlight of the presentation, showcasing the brand's forward-thinking approach in incorporating Nobel Prize-derived technology into product iteration, achieving early discovery and application, and standing tall at the forefront of the industry after many years.

As early as 2009, Estee Lauder's fifth-generation Little Brown Bottle first applied circadian gene synchronization technology and introduced the new concept of 'circadian rhythm,' which became the basis for the Nobel Prize in Medicine in 2017 and is still utilized in the current seventh-generation Little Brown Bottle. It employs 60 million selected patented peptide small molecules, penetrating layer by layer with a weight of only 302 daltons, precisely adjusting cellular circadian rhythms and accelerating the cell's nighttime repair capabilities.

In 2013, the sixth-generation Little Brown Bottle serum upgraded to include circadian gene biological rhythm technology and cellular metabolism purification technology, allowing one drop to activate gene-level repair, stimulate cellular autophagy regeneration, and accelerate cellular metabolism. It once again foresightedly applied Nobel Prize-derived technology to product research and development, continuously pushing forward as an industry benchmark that leads cutting-edge skincare technology.

Additionally, Estee Lauder, relying on epigenetics, has focused on studying the role of an epigenetic signaling factor, microRNA, in the process of skin aging. It applied a new circadian gene signaling technology in the seventh-generation Little Brown Bottle serum launched in 2020, where specific active ingredients can enhance the expression of microRNA-146a in aging skin cells, helping the skin improve the natural renewal of its new cells and promote the generation of natural collagen, further accelerating the cellular nighttime renewal force, integrating Nobel Prize-derived technology into the research of the Little Brown Bottle family's products ahead of the award received four years later.

02

Baihui Medical upgrades its brand and increases investment in China.

On December 11, the 20th anniversary of Baihui Medical's entry into China and the brand upgrade ceremony were held in Shanghai. Baihui Medical is under the IHH Healthcare Group, one of the largest private Medical Services networks in the world. For twenty years, it has been deeply cultivating the Chinese market, always adhering to the service concept of 'patient-centered', introducing international high-standard Medical Services into China. At the ceremony, attendees jointly illuminated the launch device, witnessing the new upgrade of Baihui Medical’s brand strategy. Baihui Medical will take 'Precise Care, Excellence for You' as the brand philosophy, and through accurate understanding of each patient's situation, develop scientific and personalized diagnosis and treatment plans, providing comprehensive Professional Services and targeted long-term care for patients with refined continuous care.

Against the backdrop of deepening opening policies in the Chinese Medical field, Baihui Medical is promoting a comprehensive upgrade of its service configuration in China through specific measures such as renewing its Baihui Medical Shanghai Ruipu Clinic located in the Jinqiao area of Pudong New District. Moreover, it is expected that in 2025, a new large flagship Medical center will open at a landmark location on Huaihai Middle Road in Shanghai - Shanghai Plaza. The center, covering nearly 7,000 square meters, will provide multidisciplinary Medical Services to meet patients' diverse health needs, including internal medicine, surgery, gynecology, pediatrics, and more. The center places a high emphasis on patient privacy and comfort, specially setting up single observation rooms to create a reassuring clinical environment. Additionally, the center is equipped with advanced surgical instruments and hundred-level laminar flow operating rooms, as well as a multilingual, multidisciplinary medical team, greatly facilitating communication and diagnosis for domestic and international patients, ensuring that each patient can enjoy smooth and personalized Medical Services.

Since entering the Chinese market in 2004, Baihui Medical has accompanied and witnessed the rapid development of China's Medical Industry. Over twenty years, Baihui Medical has gradually expanded its local Medical Services landscape, establishing a comprehensive service network that includes general hospitals, medical centers, and specialized clinics. Baihui Medical has nearly one hundred experienced professional physicians from over 20 countries including the USA, Germany, and France, providing patients with comprehensive and personalized Medical solutions based on international clinical disease diagnosis and multidisciplinary treatment experience, meeting both the physical and psychological needs of patients.

03

Clinique leads a new concept of 'cosmetic and medical combination'.

Clinique, a skincare brand under Estee Lauder Group that focuses on active dermal research, presented its latest research results in skin surgery post-operative pigment management strategy and new product 'CX Class II medical instruments' at the 19th Annual Meeting of the Chinese Dermatology Association (2024 CDA). At this year’s conference, Clinique's booth featured an immersive professional dermatology skincare display, showcasing all product lines in a linear fashion, providing a comprehensive and systematic presentation of the developments in their field. Clinique demonstrated four combined solutions of 'whitening and spot removal', 'oil control and acne treatment', 'high-efficiency moisturizing', and 'wrinkle reduction and firmness', achieving another breakthrough in efficacy and technological innovation.

With the popularity of light medical beauty projects, the demand for post-operative care has emerged, becoming the core theme of this year's CDA annual meeting Clinique Satellite seminar. Among them, skin whitening, as one of the strongest and most widespread needs in the diversified skincare concepts of Chinese consumers, is also a field that Clinique continues to delve into. At the conference, Professor Xiang Lei Hong from the dermatology department of Huashan Hospital affiliated with Fudan University first introduced in detail the mechanisms of skin whitening and the research and development of active ingredients. Subsequently, Dr. Zhou Huan Jun, Chief Scientist of Clinique Asia-Pacific and Director of Advanced Technology at Estee Lauder Group, also analyzed in detail the principles of melanin production from aspects such as generation, transfer, accumulation, and precipitation.

Clinique not only brought new ideas for skin whitening but also broke the cosmetic barriers with new products — two new items from the Clinique CX professional research series: recombinant collagen wound dressings and recombinant collagen composite liquid dressings. Using medical-grade 100% human-derived recombinant type III collagen combined with medical-grade sodium hyaluronate "HA-MDII," they have created the industry's first dual-repair formulation, forming a physical barrier protection layer on the surface of the wound to create a suitable healing microenvironment and promote moist healing of the wound. It is suitable for small wounds, abrasions, cuts, and other non-chronic wounds as well as care of surrounding skin.

Dr. Zhu Jin Jin, an attending physician in the dermatology department of Wuhan Hiap Hoe Hospital, pointed out that scientific and professional post-operative wound care can not only alleviate post-operative discomfort but also repair the damaged skin barrier within 1-2 weeks, achieving better skin condition and realizing true "effective medical beauty." Dr. Zhou Huan Jun, in his sharing of applications in the field of wound healing, stated that the CX recombinant collagen mother bottle with high-concentration recombinant type III human-derived collagen and medical instruments-grade sodium hyaluronate HA-MDII composite system has been clinically proven to effectively target non-chronic wound healing and promote cell migration, thus enhancing wound healing.